observational/translational study for nivolumab treatment in advanced esophageal cancer

observational/translational study for nivolumab treatment in advanced esophageal cancer - observational/translational study for nivolumab treatment in advanced esophageal cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000043208

Enrollment

Registered

2021-02-01

Start date

2020-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients with histologically confirmed diagnosis of squamaous cell carcinoma of the esophageal cancer. (2) Patients treated with nivolumab. (3) 20 years of age or more. (4) ECOG performance status 0-2. (5) Patients with potential to collect saliva and feces. (6) expected more than 3 months (6) Written informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients previously received major gastrointestinal surgery (2) Patients previously treated with nivolumab. (3) Patients who are regarded as inadequate for study enrollment by investigators.

Design outcomes

Primary

Measure	Time frame
overall survival	—

Secondary

Measure	Time frame
progression-free survival, response rate, safety, dose intensity, biomarker analysis	—

Countries

Japan

Contacts

Public ContactShintaro Nakano

Hokkaido university hospital Divison of Cancer Center

shintaro-n@frontier.hokudai.ac.jp0117161161

Outcome results